PH-762
Cutaneous Squamous Cell Carcinoma (Stages I, II, IV), Stage IV Melanoma, Stage IV Merkel Cell Carcinoma
Key Facts
Indication
Cutaneous Squamous Cell Carcinoma (Stages I, II, IV), Stage IV Melanoma, Stage IV Merkel Cell Carcinoma
Phase
Phase 1b
Status
Active - Neoadjuvant dose escalation study
Company
About Phio Pharmaceuticals
Phio Pharmaceuticals leverages its proprietary INTASYL self-delivering siRNA technology to develop next-generation immuno-oncology therapeutics. Co-founded by Nobel laureate Craig Mello, the company is advancing a clinical-stage pipeline targeting proteins like PD-1 and BRD4 to enhance anti-tumor immunity. With a strategic pivot from discovery to development under new leadership, Phio is focused on key initiatives in cutaneous squamous cell carcinoma and melanoma, aiming to overcome limitations of current immunotherapies.
View full company profile